It doesn’t have to be at Levy Rink, or any rink — some old school pond hockey would suffice for these two programs.

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Bioventus (BVS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

Shares of medical device concern Bioventus Inc. have more than tripled off their May 4th intraday low as a decent Q1 2023 report and the return of its ex-CEO have provided confidence. That said, ...

Bioventus Inc (NASDAQ:BVS) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $138.20 million, and the earnings are expected to come in at $0.03 per ...

On Tuesday, Bioventus Inc. (NASDAQ:BVS) reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents. The medical device company reported sales of $153.6 million ...

BVS is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of BVS shares has decreased $0.10 since the market last closed. This is a 1.33% ...

The Absorb GT1 bioresorbable vascular scaffold (BVS, Abbott Vascular) will no longer be widely available in Europe as of May 31, 2017, with the company restricting use of the device to centers ...